Feasibility of Allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 3, 2013, Pages 296-301

  Kebriaei, Partow ^a   Wilhelm, Kaci ^a   Ravandi, Farhad ^a   Brandt, Mark ^a   De Lima, Marcos ^a   Ciurea, Stefan ^a   Worth, Laura ^a   O'Brien, Susan ^a   Thomas, Deborah ^a   Champlin, Richard E ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Allogeneic hematopoietic stem cell transplantation; Inotuzumab ozogamicin; Venoocclusive disease

Indexed keywords

INOTUZUMAB OZOGAMICIN; METHOTREXATE; TACROLIMUS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; BLOOD DONOR; CHILD; CLINICAL ARTICLE; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; REMISSION; SALVAGE THERAPY; SCHOOL CHILD; UMBILICAL CORD BLOOD; UNRELATED DONORS; VEIN OCCLUSION;

ADOLESCENT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84877733104     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.12.003     Document Type: Article

References (32)

1. D.A. Thomas, S. Faderl, S. O'Brien Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia Cancer 106 2006 1569 1580
2. D.A. Thomas, S. O'Brien, S. Faderl Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia J Clin Oncol 28 2010 3880 3889
3. D. Hoelzer, N. Gökbuget Chemoimmunotherapy in acute lymphoblastic leukemia Blood Rev 26 2012 25 32
4. H. Kantarjian, M. Talpaz, S. O'Brien High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood 103 2004 2873 2878 (Pubitemid 38451654)
5. M. Ohanian, J. Cortes, H. Kantarjian Tyrosine kinase inhibitors in acute and chronic leukemias Expert Opin Pharmacother 13 2012 927 938
6. F. Ravandi, S. O'Brien, D. Thomas First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia Blood 116 2010 2070 2077
7. D.A. Thomas, S. Faderl, J. Cortes Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood 103 2004 4396 4407 (Pubitemid 38745962)
8. N. Gokbuget, D. Hoelzer, R. Arnold Treatment of adult ALL according to protocols of the German Multicenter Study Group for adult ALL (GMALL) Hematol Oncol Clin North Am 14 2000 1307 1325 ix
9. R. Bassan, D. Hoelzer Modern therapy of acute lymphoblastic leukemia J Clin Oncol 29 2011 532 543
10. S. Faderl, S. O'Brien, C.H. Pui Adult acute lymphoblastic leukemia: concepts and strategies Cancer 116 2010 1165 1176
11. N. Gökbuget, D. Hoelzer Treatment of adult acute lymphoblastic leukemia Semin Hematol 46 2009 64 75
12. E.A. Raetz, M.S. Cairo, M.J. Borowitz Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study J Clin Oncol 26 2008 3756 3762
13. M.S. Topp, P. Kufer, N. Gökbuget Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival J Clin Oncol 29 2011 2493 2498
14. A.K. Fielding, S.M. Richards, R. Chopra Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study Blood 109 2007 944 950 (Pubitemid 46220637)
15. P. Kozlowski, M. Åström, L. Ahlberg High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007 Haematologica 97 2012 1414 1421
16. E. Tavernier, J.M. Boiron, F. Huguet Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial Leukemia 21 2007 1907 1914 (Pubitemid 47299963)
17. J.S. Thorson, E.L. Sievers, J. Ahlert Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research Curr Pharm Des 6 2000 1841 1879
18. H. Kantarjian, D. Thomas, J. Jorgensen Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study Lancet Oncol 13 2012 403 411
19. P. Kebriaei, R. Saliba, G. Rondon Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes Biol Blood Marrow Transplant 18 2012 584 592
20. D. Przepiorka, D. Weisdorf, P. Martin Consensus Conference on Acute GVHD Grading Bone Marrow Transplant 1995 1994 825 828
21. L.D. DeLeve, H.M. Shulman, G.B. McDonald Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease) Semin Liver Dis 22 2002 27 42
22. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Amer Statist Assn 53 1958 457 481
23. D.A. Thomas, H. Kantarjian, T.L. Smith Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy Cancer 86 1999 1216 1230 (Pubitemid 29447005)
24. D.B. Johnson, B.N. Savani How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation? Exp Hematol 40 2012 513 517
25. E. Carreras, H. Bertz, W. Arcese Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation European Group for Blood and Marrow Transplantation Chronic Leukemia working party Blood 92 1998 3599 3604 (Pubitemid 28525185)
26. G. Ganem, M.F. Saint-Marc Girardin, M. Kuentz Venocclusive disease of the liver after allogeneic bone marrow transplantation in man Int J Radiat Oncol Biol Phys 14 1988 879 884
27. J.L. Lee, T. Gooley, W. Bensinger Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome Biol Blood Marrow Transplant 5 1999 306 315
28. P. Kebriaei, R.M. Saliba, C. Ma Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia Bone Marrow Transplant 38 2006 203 209 (Pubitemid 44102947)
29. P. Kebriaei, R. Basset, C. Ledesma Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation Biol Blood Marrow Transplant 18 2012 1819 1826
30. A. Advani, B. Coiffier, M.S. Czuczman Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study J Clin Oncol 28 2010 2085 2093
31. J.M. McKoy, C. Angelotta, C.L. Bennett Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project Leuk Res 31 2007 599 604 (Pubitemid 46578145)
32. J.H. Essell, M.T. Schroeder, G.S. Harman Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation A randomized, double-blind, placebo-controlled trial Ann Intern Med 128 1998 975 981 (Pubitemid 28275173)